Peptides DB
Research-centric peptide and protocol reference hub
Study 8 of 9Teduglutide literatureClinical nutrition ESPEN · Observational2021

Glucagon-like peptide 2 analogues in the treatment of intestinal failure: A qualitative exploration of the views of patients and their families in decision making.

Patients with short bowel syndrome may see the potential benefits of teduglutide as outweighing the risks, while family members may have more reservations about the treatment.

Read at Clinical nutrition ESPENAdd to compare

Where it sits

this study against the rest of the teduglutide corpus
0
Preclinical
8
Observational · this one
0
Open-label
0
Randomised
1
Reviews

Summary and findings

This qualitative study explored the decision-making process of patients with short bowel syndrome and type 3 intestinal failure regarding teduglutide. Nine participants, including six patients and three family members, were interviewed about their motivations and concerns related to starting the treatment. The study found that motivations included reducing dependence on parenteral nutrition, while concerns focused on potential side effects and the need for monitoring.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2021

Abstract

The authors’ words, as Clinical nutrition ESPEN supplied them

<h4>Background and aims</h4>Patients with short bowel syndrome and type 3 intestinal failure (SBS-IF) are dependent on parenteral nutrition (PN), a lifesaving treatment but inconvenient and with risks. Glucagon-like peptide 2 analogue (teduglutide) can reduce patients' need for PN. However, it comes with the risk of a number of side effects. This qualitative study investigated patients' decision making process to start teduglutide and how family members contributed to the decision.<h4>Methods</h4>In-depth semi-structured interviews were conducted with nine participants, six patients with SBS-IF and three family members about the decision to take teduglutide. Interviews were transcribed verbatim and analysed using framework analysis.<h4>Results</h4>The prominent motivation for taking teduglutide (Revestive® Takeda Pharmaceuticals Limited) was reducing or stopping PN. Other motivations were to help others by assisting in developing the knowledge base around teduglutide, patients felt that they had nothing to lose by trying the drug and the support of relatives. The reasons patients considered not taking the drug were that they had accepted being on PN, the potential side effects of teduglutide and undergoing extra monitoring. However, the monitoring programme also acted as a motivator providing reassurance that patients would be observed and supported with side effects. Family members were happy to support patients' decision to try teduglutide, although they had more reservations, indicating a higher risk threshold.<h4>Conclusion</h4>Patients considered potential benefits of teduglutide outweighed any disadvantages. Relatives, although supportive, had more reservations.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Teduglutide corpus

CPharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.The Journal of pharmacology and experimental therapeutics · 2020 · Clearance rates: hGLP-2 25 ml/kg/min, teduglutide 9.9 ml/kg/min, glepaglutide 2.8 ml/kg/min, apraglutide 0.27 ml/kg/min.AnimalBManagement of Short Bowel Syndrome/Chronic Intestinal Failure – the Experience of a Single Portuguese Centerbiorxiv-preprint · 2024 · n=13 · Median time of HPN for eight patients alive was 173 months.HumanDImpact of Teduglutide on Pediatric Short Bowel Syndrome: Protocol for a Systematic Review and Trial Sequential Meta-Analysisbiorxiv-preprint · 2025 · Not reported in abstract.reviewBTeduglutide in Enterocolitis Secondary to Graft-Versus-Host Disease Post-Bone Transplant: Case Reportbiorxiv-preprint · 2026 · Not reported in abstract.HumanCGLP-2 prevents antipsychotics-induced metabolic dysfunction in mice.Nature metabolism · 2025 · Not reported in abstract.AnimalBPersonalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.The Journal of clinical endocrinology and metabolism · 2026 · Not reported in abstract.Human